Sullivan Christopher Ryan (CIK 1810417) reported 27 SEC Form 4 insider transactions across 1 companies over the past 18 months (most recent 2026-08-19). Recent activity: Buy AVTX (37,945 shares), Buy AVTX (2,876 shares), Sell AVTX (37,945 shares), Sell AVTX (3,749 shares), Buy AVTX (31,031 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-19 | Avalo Therapeutics, Inc. (AVTX) | Chief Financial Officer | Buy | 37,945 | $374,897 |
| 2026-08-19 | Avalo Therapeutics, Inc. (AVTX) | Chief Financial Officer | Buy | 2,876 | $28,415 |
| 2026-08-19 | Avalo Therapeutics, Inc. (AVTX) | Chief Financial Officer | Sell | 37,945 | $753,333 |
| 2026-08-19 | Avalo Therapeutics, Inc. (AVTX) | Chief Financial Officer | Sell | 3,749 | $74,762 |
| 2026-08-19 | Avalo Therapeutics, Inc. (AVTX) | Chief Financial Officer | Buy | 31,031 | $306,586 |
| 2026-08-19 | Avalo Therapeutics, Inc. (AVTX) | Chief Financial Officer | Sell | 31,031 | $622,324 |
| 2026-06-12 | Avalo Therapeutics, Inc. (AVTX) | Chief Financial Officer | Sell | 138 | $1,808 |
| 2026-05-26 | Avalo Therapeutics, Inc. (AVTX) | Chief Financial Officer | Buy | 39,900 | $0 |
| 2026-05-11 | Avalo Therapeutics, Inc. (AVTX) | Chief Financial Officer | Buy | 18,606 | $183,827 |
| 2026-05-11 | Avalo Therapeutics, Inc. (AVTX) | Chief Financial Officer | Sell | 18,606 | $448,818 |
| 2026-05-07 | Avalo Therapeutics, Inc. (AVTX) | Chief Financial Officer | Sell | 12,347 | $238,093 |
| 2026-05-07 | Avalo Therapeutics, Inc. (AVTX) | Chief Financial Officer | Sell | 13,834 | $256,655 |
| 2026-05-07 | Avalo Therapeutics, Inc. (AVTX) | Chief Financial Officer | Buy | 47,000 | $377,880 |
| 2026-05-07 | Avalo Therapeutics, Inc. (AVTX) | Chief Financial Officer | Sell | 2,700 | $56,052 |
| 2026-05-07 | Avalo Therapeutics, Inc. (AVTX) | Chief Financial Officer | Sell | 9,219 | $197,008 |
| 2026-05-07 | Avalo Therapeutics, Inc. (AVTX) | Chief Financial Officer | Sell | 8,900 | $200,913 |
| 2026-05-01 | Avalo Therapeutics, Inc. (AVTX) | Chief Financial Officer | Sell | 8,458 | $110,736 |
| 2026-05-01 | Avalo Therapeutics, Inc. (AVTX) | Chief Financial Officer | Sell | 8,457 | $111,853 |
| 2026-04-03 | Avalo Therapeutics, Inc. (AVTX) | Chief Financial Officer | Sell | 500 | $7,929 |
| 2026-04-03 | Avalo Therapeutics, Inc. (AVTX) | Chief Financial Officer | Sell | 7,479 | $125,841 |
| 2026-04-03 | Avalo Therapeutics, Inc. (AVTX) | Chief Financial Officer | Sell | 6,200 | $105,553 |
| 2026-04-03 | Avalo Therapeutics, Inc. (AVTX) | Chief Financial Officer | Sell | 1,780 | $31,270 |
| 2026-03-31 | Avalo Therapeutics, Inc. (AVTX) | Chief Financial Officer | Buy | 24,200 | $0 |
| 2026-03-31 | Avalo Therapeutics, Inc. (AVTX) | Chief Financial Officer | Sell | 8,241 | $114,467 |
| 2025-12-12 | Avalo Therapeutics, Inc. (AVTX) | Chief Financial Officer | Sell | 155 | $636 |
Source: SEC Form 4 filings · as of 2026-08-19